Treatment with antiepileptic drugs does not increase the risk of skin cancer, but an association has been observed between use of carbamazepine and lamotrigine and squamous cell carcinoma (SCC), a recent study has shown.
Poorly differentiated cutaneous squamous cell carcinomas (cSCCs) are likely to be incompletely excised in peripheral and deep planes, despite adherence to the British Association of Dermatology-British Association of Plastic, Reconstructive and Aesthetic Surgery guidelines, reports a recent UK study.
Topical immunotherapy with squaric acid dibutylester appears to be effective in the treatment of alopecia areata, according to a study, lending support to current treatment guidelines recommending the use of topical immunotherapies.
Placebo responses appear to be common in randomized controlled trials for atopic dermatitis, reports a new meta-analysis. Better methodological control, such as double- or triple-blinding and more balanced sex distributions, may help address this.
Treatment with tumour necrosis factor-alpha (TNFα) inhibitor may likely lead to an increase in body weight and body mass index (BMI) in patients with psoriasis, whereas treatment with anti-interleukin (IL)-12/23 and IL-17 biologics does not, results of a recent systematic review and meta-analysis have shown.
In clinical trials of systemic therapy in atopic dermatitis (AD), the integration of double- and triple-blinding can lower placebo responses, according to the results of a systematic review and meta-analysis. Other means of achieving this include balancing of patient sex distribution, disallowing concomitant use of prescription topical therapy and having shorter study durations.
Biologic therapies for psoriasis may need to be switched between classes to increase drug survival in patients, suggest a recent study. Ad hoc retrospective studies are needed to confirm the benefits of this switching strategy.
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.